Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KLKB1 | P03952 | 3/20 | 0.55 |
| ▸ | F10 | P00742 | 6/20 | 0.55 |
| ▸ | PTGS2 | P35354 | 5/20 | 0.49 |
| ▸ | PTGS1 | P23219 | 4/20 | 0.49 |
| ▸ | GRN | P28799 | 1/20 | 0.46 |
| ▸ | SORT1 | Q99523 | 1/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.44 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.44 |
| ▸ | THPO | P40225 | 1/20 | 0.44 |
| ▸ | BLM | P54132 | 1/20 | 0.44 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.44 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.44 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.44 |
| ▸ | ORAI1 | Q96D31 | 1/20 | 0.44 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.43 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31067446 | 1.00 | KLKB1 (0.55) | KLKB1F10PTGS2PTGS1GRN | |
| SCHEMBL18604629 | 0.88 | PTGS2 (0.58) | KLKB1PTGS2PTGS1GRNSORT1 | |
| SCHEMBL5584120 | 0.85 | KLKB1 (0.69) | KLKB1GRNSORT1TRPV1MEN1 | |
| SCHEMBL6763739 | 0.80 | F10 (0.61) | F10 | |
| SCHEMBL3224886 | 0.79 | HTT (0.50) | KLKB1PTGS2PTGS1GRNSORT1 | |
| SCHEMBL21462630 | 0.78 | KLKB1 (0.59) | KLKB1PTGS2PTGS1GRNSORT1 | |
| SCHEMBL950904 | 0.78 | GRN (0.72) | KLKB1PTGS2PTGS1GRNSORT1 | |
| SCHEMBL30677091 | 0.77 | KLKB1 (0.57) | KLKB1PTGS2PTGS1GRNSORT1 | |
| SCHEMBL18218817 | 0.77 | GRN (0.62) | KLKB1PTGS2PTGS1GRNSORT1 | |
| SCHEMBL1096199 | 0.76 | PTGS2 (0.61) | KLKB1F10PTGS2PTGS1GRN |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 56 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4663636-A2 | TRIFLUOROMETHYL SUBSTITUTED PYRAZOLES AS HUMAN PLASMA KALLIKREIN INHIBITORS | BioCryst Pharmaceuticals, Inc. (US) | 2025-12-17 | — | — | EP | disclosed |
| US-20250270171-A1 | HUMAN PLASMA KALLIKREIN INHIBITORS | WILMINGTON TRUST, NATIONAL ASSOCIATION | 2025-08-28 | — | — | US | disclosed |
| US-20250257040-A1 | HUMAN PLASMA KALLIKREIN INHIBITORS | WILMINGTON TRUST, NATIONAL ASSOCIATION | 2025-08-14 | — | — | US | disclosed |
| EP-4180424-B1 | SUBSTITUTED PYRAZOLES AS HUMAN PLASMA KALLIKREIN INHIBITORS | BIOCRYST PHARM INC (US) | 2025-06-25 | — | — | EP | disclosed |
| US-12162838-B2 | Human plasma kallikrein inhibitors | BIOCRYST PHARMACEUTICALS, INC. (US) | 2024-12-10 | — | — | US | disclosed |
| US-12116346-B2 | Human plasma kallikrein inhibitors | BIOCRYST PHARMACEUTICALS, INC. (US) | 2024-10-15 | — | — | US | disclosed |
| CN-113307772-B | Human plasma kallikrein inhibitors | 拜奥克里斯特制药公司 | 2024-06-28 | — | — | CN | disclosed |
| US-20240150295-A1 | HUMAN PLASMA KALLIKREIN INHIBITORS | WILMINGTON TRUST, NATIONAL ASSOCIATION | 2024-05-09 | — | — | US | disclosed |
| US-20240150296-A1 | HUMAN PLASMA KALLIKREIN INHIBITORS | WILMINGTON TRUST, NATIONAL ASSOCIATION | 2024-05-09 | — | — | US | disclosed |
| US-11708332-B2 | Human plasma kallikrein inhibitors | BIOCRYST PHARMACEUTICALS, INC. (US) | 2023-07-25 | — | — | US | disclosed |
| US-20180354906-A1 | HUMAN PLASMA KALLIKREIN INHIBITORS | WILMINGTON TRUST, NATIONAL ASSOCIATION | 2018-12-13 | — | — | US | disclosed |
| US-10125102-B2 | Human plasma kallikrein inhibitors | BIOCRYST PHARMACEUTICALS, INC. (US) | 2018-11-13 | — | — | US | disclosed |
| US-20180258049-A1 | HUMAN PLASMA KALLIKREIN INHIBITORS | WILMINGTON TRUST, NATIONAL ASSOCIATION | 2018-09-13 | — | — | US | disclosed |
| US-20170073314-A1 | HUMAN PLASMA KALLIKREIN INHIBITORS | WILMINGTON TRUST, NATIONAL ASSOCIATION | 2017-03-16 | — | — | US | disclosed |
| US-20170073314-A1 | HUMAN PLASMA KALLIKREIN INHIBITORS | WILMINGTON TRUST, NATIONAL ASSOCIATION | 2017-03-16 | — | — | US | disclosed |
| EP-3113772-A1 | HUMAN PLASMA KALLIKREIN INHIBITORS | Biocryst Pharmaceuticals, Inc. (US) | 2017-01-11 | — | — | EP | disclosed |
| WO-2015134998-A1 | HUMAN PLASMA KALLIKREIN INHIBITORS | BIOCRYST PHARMACEUTICALS, INC. (US) | 2015-09-11 | — | — | WO | disclosed |
| US-20040116399-A1 | Inhibitors of factor Xa | MILLENNIUM PHARMACEUTICALS, INC. | 2004-06-17 | — | — | US | disclosed |
| US-6632815-B2 | Show selectivity for factor Xa versus other proteases of coagulation or the fibrinolytic cascades | MILLENNIUM PHARMACEUTICALS, INC. | 2003-10-14 | — | — | US | disclosed |
| US-20020091116-A1 | Show selectivity for factor Xa versus other proteases of coagulation or the fibrinolytic cascades | MILLENNIUM PHARMACEUTICALS, INC. | 2002-07-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (12 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180354906-A1 | HUMAN PLASMA KALLIKREIN INHIBITORS | KLKB1, KLK1, KLK5 | KLKB1 1/4885F10 143/4885PTGS2 1712/4885 |
| US-20020091116-A1 | Show selectivity for factor Xa versus other proteases of coagulation or the fibrinolytic cascades | SERPINC1, TFPI, F2 | KLKB1 67/4885F10 11/4885PTGS2 1996/4885 |
| US-12116346-B2 | Human plasma kallikrein inhibitors | KLKB1, KLK5, KLK1 | KLKB1 1/4885F10 112/4885PTGS2 1260/4885 |
| US-20250270171-A1 | HUMAN PLASMA KALLIKREIN INHIBITORS | KLKB1, KLK5, KLK1 | KLKB1 1/4885F10 112/4885PTGS2 1260/4885 |
| US-20240150296-A1 | HUMAN PLASMA KALLIKREIN INHIBITORS | KLKB1, KLK5, KLK1 | KLKB1 1/4885F10 112/4885PTGS2 1260/4885 |
| US-11708332-B2 | Human plasma kallikrein inhibitors | KLKB1, KLK5, KLK1 | KLKB1 1/4885F10 115/4885PTGS2 1377/4885 |
| US-10125102-B2 | Human plasma kallikrein inhibitors | KLKB1, KLK1, KLK5 | KLKB1 1/4885F10 143/4885PTGS2 1712/4885 |
| US-20170073314-A1 | HUMAN PLASMA KALLIKREIN INHIBITORS | KLKB1, KLK1, KLK5 | KLKB1 1/4885F10 143/4885PTGS2 1712/4885 |
| US-20240150295-A1 | HUMAN PLASMA KALLIKREIN INHIBITORS | KLKB1, KLK5, KLK1 | KLKB1 1/4885F10 112/4885PTGS2 1260/4885 |
| US-20250257040-A1 | HUMAN PLASMA KALLIKREIN INHIBITORS | KLKB1, KLK5, KLK1 | KLKB1 1/4885F10 112/4885PTGS2 1260/4885 |
| US-20180258049-A1 | HUMAN PLASMA KALLIKREIN INHIBITORS | KLKB1, KLK1, KLK5 | KLKB1 1/4885F10 143/4885PTGS2 1712/4885 |
| US-12162838-B2 | Human plasma kallikrein inhibitors | KLKB1, KLK5, KLK1 | KLKB1 1/4885F10 112/4885PTGS2 1260/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.